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576 Abstracts
90 to 109 mm Hg) with renal function ranging from normal to severely 
impaired. Time control data were obtained after administration of vehicle. 
GFR and ERPF were measured as the clearances of 125I-iothalamate and 
m I-hippuran, respectively. Seventeen patients were included (4 with GFR 
<  30, 5 with GFR 30 to 60, and 8 with GFR >  60 ml/min). Results 
(median and 95% Cl) are expressed as a percentage change. For the single 
dose these changes are corrected for diurnal variations.
Pre-treatment Single dose
Maintenance 
% change
MAP mm Hg 118(107 to 126) — 8 (—14 to - 5 ) il -11  ( - 1 6  to - 5 ) h
ERPF ml/min 256 (203 to 412) 13 (7 to 19)a 1 Ü (3 to 14)
GFR mlfmin 60 (49 to 94) 2  (—2 to 6) 0 ( 7 to 2)
FF 0.23 (0,22 to 0.26) - 1 1  ( - 1 4  to - 5 ) :i - 1 2  ( - 1 3  to - 4 ) h
RVR 24 (15 to 47) - 1 8  ( - 2 2  to - 1 3 ) u -1 3  ( - 2 5  to 0)”
dyne • s
*  cm ' “
“P <  0.01 vs. pre-treatment, hP <  0.01 vs. baseline
Treatment with candesartan resulted in a fall in blood pressure. The rise 
in ERPF and the fall in FF after a single dose was more pronounced in 
patients with normal GFR as shown by the correlation between initial 
GFR and percentage change in ERPF and FF (both P <  0.05). These 
results suggest that renal vasodilation was more pronounced in patients 
with normal renal function. Interestingly, on maintenance treatment, 
these correlations were absent, indicating that renal vasodilation occurs 
then both in patients with normal and impaired renal function* No 
correlations were found between changes in blood pressure and renal 
hemodynamics. In conclusion, candesartan cilexilil induces renal vasodi­
lation during continued treatment. This can be achieved not only in 
patients with normal renal function but also in patients with impaired 
renal function.
Intravenous iron in dialysis patients: Adjust EPO dose? P.M. van dcr 
Stmde, E.C.M. van Pampas, ICiVLL, Leunissen, and. J.NM. BarendregU 
Department o f  Internal Medicine, Academic Hospital Maastricht, The Neth­
erlands. The optimal adjustment of recombinant erythropoietin (EPO) 
dose after initiation of intravenous iron therapy (ivFc), to avoid progres­
sive anemia or polyglobulinemia, is unknown. We performed a prospective 
randomized trial to study the possibility of reducing the EPO dose after 
initiation of ivFe in relatively “ iron deplete1 dialysis patients (serum 
ferritin <  100 mg/liter or transferrin saturation <  20%). After a run-in 
period of 3 months, during which iron was administered orally (ferrosi 
fumaras 0.2 g thrice daily), stable ’’iron deplete’ patients were randomized 
to receive 0%, 50% or 100% of their original weekly subcutaneous EPO 
(Eprex, Jansen-Cilag) dose and intravenously 100 mg iron saccharate 
(Venoferrum, Fresenius) bi-weekly during 3 months. Hematocrit (Hct), 
ferritin (FER, mg/liter), transferrin saturation (TRS, %) and need for 
transfusion of packed erythrocytes or adjustment of EPO dose (TRANS, 
%  of group developing severe anemic symptoms and/or having a decline of 
Hct larger than 0.12 or below 0.25) were measured at least at beginning 
and end of each period. Pre-transfusion Hct values are reported in 
transfused patients. During the run-in period the EPQ-0% (N = 7), the 
EPO-50% (N — 10) and the EPG-100% (N  = 12) groups were similar 
regarding age (68 ±  9 years), time on dialysis (3.4 ± 2.7 years), EPO dose 
(7.5 +  3.1 kU), Hct (0.33 ±  0.05), FER (61 ±  51), TRS (19 ± 8%) and 
TRANS (31%). After start of ivFe, FER increased by 120 ±  16, P <  0.01 
in all groups. TRS increased by 4.0 ± 1.6% in the EPC-0% group and by 
4.0 ± 1.8% in the EPO-50% group, both P <  0.05, and remained 
unchanged in the EPO-JOO% group. TRANS increased by 57% in the 
EPO>0%, P <  0.05, remaining unchanged in the other groups. Hct 
decreased by 0.04 ± 0.01, P  <  0.05 in the EPO-50% group. The study 
indicates that replacement of ferrosi fumaras by intravenous iron sac­
charate in “iron deplete’ hemodialysis patients increases FER and TRS. 
Reduction of EPO dose at the start of ivFe is ill-advised because it reduces 
Hct values and increases the need for transfusions within the first 3 
months.
Fracture incidence after kidney transplantation. R. dc Sevaitx, J. Wetzels 
and A. Hoitsma, Department o f  Nephrology, University Hospital Nijmegen, 
The Netherlands. Several long-term complications occur after successful
kidney transplantation» One of these is corticosteroid-induced osteoporo 
sis, resulting in fractures. Retrospectively we determined the fractun 
incidence in our patients as follows: all patients with good graft function 
transplanted before January 1st, 1988, were sent a questionnaire and tliei 
medical records were studied. We asked for the occurrence of fracture: 
after transplantation, the existence of osteoporosis and a possible therap) 
for osteoporosis. A total of 292 patients were identified (165 men, 12' 
women). The mean age at transplantation for men was 35 years (range A 
to 69 years) and for women 36 years (range 5 to 61). Two hundred and 
sixteen questionnaires (74%) were returned, 284 medical records were 
reviewed (98%). In this way we obtained data on 290 of 292 patients, The 
mean duration of follow-up for men was 13 years (range 8 to 27 years) and 
for women 14 years (range 8 to 25 years). Sixty-eight fractures occurred in 
43 patients (17 men, 26 women); in most of the cases there was only a 
minor or no trauma. Fractures were situated in leg/ankle/foot (25x in 20 
patients), arm/wrist/hand (23X in 16 patients), ribs (6X in 6 patients), 
pelvis (2X in 2 patients), vertebrae (in 10 patients), sternum (IX) and 
clavicle (1X). In half of the cases, the first fracture occurred within 5 years 
after transplantation. Fractures occurred significantly more often in 
women (P <  0.02). The time on dialysis before, and the cumulative dose 
of corticosteroids in the first 3 months after transplantation did not differ 
between man or women with or without a fracture. Women with one or 
more fractures were transplanted at a significant older age (42 vs. 35 years; 
P <  0.05) and were significantly older at the moment of follow-up than 
women without fractures (55 vs. 48 years; P <  0.05); the duration of 
follow-up was 14 years in both groups. Fractures were confirmed radio- 
logically; in 19/43 patients signs of osteoporosis were seen on these 
radiographs. In 9 of these 19 patients densitometry was performed; 8 of 
them indeed had osteoporosis and were intermittently treated for osteo­
porosis. In the whole group of 292 patients, 28 were treated for osteopo­
rosis; 14 of them had fractures before this treatment, Our conclusions arc: 
15% of our patients experienced one or more fractures after kidney 
transplantation and there is an apparent correlation with osteoporosis.
Prediction of overhydration in hemodialysis (HD) patients by measur­
ing blood pressure response to Valsalva maneuver. DJ. W. van Kraaij, 1H. 
Goy M.MJ. Schiainnans, R.W.MM. Jansen, W.H.L Hoejhagels, Depart­
ment of Internal Medicine, Canisius- Wilheli11ina Hospital and Department of 
Geriatric Medicine, University Hospital Nijmegen, Nijmegen, The Nether­
lands. Distinct correlations between the systolic blood pressure ratio 
during a pressure-monitored Vafsalva maneuver and pulmonary wedge 
pressure have been demonstrated previously. We performed non-invasivc 
blood pressure measurements (FinapresK) during Valsalva maneuvers in 
15 patients on chronic HD, and compared the use of this procedure in 
identifying overhydrated HD patients with four other methods. During the 
five-week study period, 5 patients experienced an episode of overhydra- 
Lion, necessitating medical intervention. Compared are predialysis means 
of pre- vs. post-overhydration periods in 5 overhydrated patients (I), and 
of 5 overhydrated patients vs. 10 controls (II).
P values”
Method I (N = 5) II (N = 15)
Blood pressure ratio during Valsalva 0.025 0.032
Composite clinical assessment score11 0.051 0.006
Weight deviation of target dry weight 0 . 1 2 1 0.436
Centra) venous pressure 0,355 0.159
Extracellular fluid volume0' 1 . 0 0 0 0,327
a Wilcoxon rank sum test
b Composed by an experienced nephrologist, including evaluation of 
thirst, dry mouth, dizziness, muscle cramps, decreased skin turgor, dys­
pnea, orthopnea, elevated centra] venous pressure, pulmonary rales and 
edema
c Bio-electrical conductivity measurements
Only blood pressure ratios and clinical assessment scores correlated well 
(/• = 0.70, P = 0.004) in all patients. In conclusion, assessment of the blood 
pressure response to a Valsalva maneuver appears to be a useful addi­
tional tool to idemify overhydrated HD patients and to evaluate the effect 
of treatment interventions in such patients.
